Reviva Pharmaceuticals Holdings Inc
Research Reviva Pharmaceuticals Holdings Inc (RVPH) on Bullrun: market cap USD 6.49M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRVPH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.49M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 16.63M
- Free cash flow-USD 20.20M
Valuation Snapshot
latest market cap is USD 6.49M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 19.86M | -USD 24.59M | n/a | -11.68 | USD 14.44M | USD 406.88K | USD 8.65M |
| FY2024 | USD 0 | -USD 29.92M | -USD 33.54M | n/a | -1.66 | USD 13.48M | USD 458.15K | USD 812.57K |
| FY2023 | n/a | -USD 39.26M | n/a | n/a | -2.96 | USD 23.37M | USD 0 | USD 5.72M |
| FY2022 | n/a | -USD 28.26M | n/a | n/a | n/a | USD 18.52M | USD 0 | USD 8.39M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.49M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 32.89M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 84.31M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 143.78M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 86.88M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 41.71M | n/a | n/a | n/a |
About Reviva Pharmaceuticals Holdings Inc
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Reviva Pharmaceuticals Holdings Inc's market cap?
Reviva Pharmaceuticals Holdings Inc's market capitalization is USD 6.49M.
What does Reviva Pharmaceuticals Holdings Inc do?
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.